Haitao Meng
Overview
Explore the profile of Haitao Meng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
529
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang B, Tong H, Meng H, Xie W, Yu W, Huang J, et al.
Blood Cancer J
. 2025 Mar;
15(1):39.
PMID: 40089468
No abstract available.
2.
Wang H, Suo S, Li D, Li J, Liu L, Lu Y, et al.
Leukemia
. 2025 Mar;
PMID: 40074854
No abstract available.
3.
Xu G, Ye X, Zhang Y, Wang W, Zhu S, Li K, et al.
Hematol Oncol
. 2025 Feb;
43(2):e70043.
PMID: 39898514
This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate-to-severe bone marrow fibrosis (MF). Among the patients with...
4.
Ye L, Yang Y, Zhang X, Wang L, Zhu L, Li X, et al.
BMC Infect Dis
. 2024 Oct;
24(1):1141.
PMID: 39394593
Purpose: The essence of this scholarly work was to carefully outline the key factors intensifying the virulence and protracted contagion of COVID-19, particularly among individuals afflicted with hematologic malignancies (HM),...
5.
Yin X, Liu Y, Lv Z, Ding S, Ma L, Yang M, et al.
Oncogene
. 2024 Aug;
43(37):2795-2805.
PMID: 39147879
The etiology of idiopathic multicentric Castleman disease (iMCD) is poorly understood, and the identification of targetable disease mediators remains an unmet clinical need. Thus, we firstly employed single-cell RNA sequencing...
6.
Liu Y, Yin X, Ding S, Ge J, Ma L, Yang M, et al.
J Hematol Oncol
. 2024 Aug;
17(1):60.
PMID: 39107807
The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We...
7.
Yao Y, Zhou Y, Zhuo N, Xie W, Meng H, Lou Y, et al.
Blood Cancer J
. 2024 Jul;
14(1):118.
PMID: 39039048
No abstract available.
8.
Feng Y, Meng H, Mu C, Zhang Y, Liu X, Shi Y, et al.
Blood Coagul Fibrinolysis
. 2024 Apr;
35(4):155-160.
PMID: 38625834
Immune thrombocytopenia (ITP) is an autoimmune disease that arises because of self-destruction of circulating platelets. The mechanism remains complicated and lacks a standard clinical treatment. Current first-line and second-line medications...
9.
You L, Liu Y, Mai W, Xie W, Zhou D, Mao L, et al.
Eur J Cancer
. 2024 Mar;
202:113979.
PMID: 38471289
Background: The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating R/R AML. Objective: This phase 2 study aimed to...
10.
Wang R, Zhang Y, Chang J, Wang H, Lou Y, Yang M, et al.
Hematol Oncol
. 2024 Feb;
42(2):e3260.
PMID: 38415873
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy (DAV) has shown safety and efficacy in eligible patients with newly diagnosed acute myeloid leukemia (AML). However, there are no direct...